Literature DB >> 11967026

Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome.

Nosratola D Vaziri1, Kaihui Liang.   

Abstract

BACKGROUND: We have previously demonstrated that hypercholesterolemia in rats with puromycin-induced nephrotic syndrome (NS) is associated with up-regulation of hepatic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and relative down-regulation of cholesterol 7alpha-hydroxylase (Ch-7alpha), which represent the rate-limiting steps in cholesterol biosynthesis and catabolism. Expression of HMG-CoA reductase is inhibited and Ch-7alpha is augmented by intracellular free cholesterol, which is avidly esterified by acyl-CoA:cholesterol acyltransferase (ACAT). Therefore, we hypothesized that NS may result in up-regulation of hepatic ACAT.
METHODS: Hepatic tissue ACAT mRNA (Northern blot), protein (Western blot) and enzymatic activity were determined in rats with puromycin-induced NS, placebo-treated control rats and Nagase hypoalbuminemic (NAG) rats.
RESULTS: The NS group exhibited heavy proteinuria, hypoalbuminemia, normal creatinine clearance, severe hypercholesterolemia and hypertriglyceridemia. Despite severe hypoalbuminemia, NAG rats with inherited hypoalbuminemia exhibited only a mild elevation of plasma cholesterol and triglycerides. Severe hypercholesterolemia in the NS group was coupled with depressed liver tissue free cholesterol concentration and marked increases in hepatic ACAT mRNA, protein and enzymatic activity. In contrast, ACAT mRNA and protein contents of the liver were normal and ACAT activity was mildly elevated in the NAG group.
CONCLUSIONS: NS results in marked up-regulation of hepatic ACAT, which is primarily due to proteinuria and not hypoalbuminemia, since the latter alone, as seen in NAG rats, does not significantly impact ACAT expression. Elevated ACAT in NS can contribute to dysregulation of cholesterol biosynthesis and catabolism by limiting the normal cholesterol signaling involved in regulation of these processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967026     DOI: 10.1046/j.1523-1755.2002.00319.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

1.  The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.

Authors:  Mary E Haas; Amy E Levenson; Xiaowei Sun; Wan-Hui Liao; Joseph M Rutkowski; Sarah D de Ferranti; Valerie A Schumacher; Philipp E Scherer; David J Salant; Sudha B Biddinger
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 2.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

Review 3.  Statins in the management of dyslipidemia associated with chronic kidney disease.

Authors:  Murray Epstein; Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

Review 4.  HDL metabolism and activity in chronic kidney disease.

Authors:  Nosratola D Vaziri; Mohamad Navab; Alan M Fogelman
Journal:  Nat Rev Nephrol       Date:  2010-03-23       Impact factor: 28.314

Review 5.  Cholesterol Metabolism in CKD.

Authors:  Allison B Reiss; Iryna Voloshyna; Joshua De Leon; Nobuyuki Miyawaki; Joseph Mattana
Journal:  Am J Kidney Dis       Date:  2015-09-01       Impact factor: 8.860

Review 6.  The genetics of neutral lipid biosynthesis: an evolutionary perspective.

Authors:  Aaron R Turkish; Stephen L Sturley
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-12-30       Impact factor: 4.310

7.  Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome.

Authors:  Seungyeup Han; Nosratola D Vaziri; Pavan Gollapudi; Vincent Kwok; Hamid Moradi
Journal:  Am J Transl Res       Date:  2013-03-28       Impact factor: 4.060

8.  Dyslipidemia associated with chronic kidney disease.

Authors:  Vasilis Tsimihodimos; Zoi Mitrogianni; Moses Elisaf
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

9.  Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.

Authors:  Huaying Shen; Sheng Feng; Ying Lu; Linsen Jiang; Tingting Yang; Zhi Wang
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

Review 10.  The non-immunosuppressive management of childhood nephrotic syndrome.

Authors:  James McCaffrey; Rachel Lennon; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2015-11-10       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.